Headquartered in Toronto, ON Fiscal year ends December NASDAQ: PMN promisneurosciences.com
ProMIS Neurosciences is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibodies and vaccines that selectively target toxic oligomers associated with neurodegenerative and other misfolded protein diseases. The company's proprietary computational platform, EpiSelect™, identifies conformational epitopes uniquely exposed on toxic misfolded proteins, enabling the generation of misfolding-specific antibodies. Its lead candidate, PMN310, is a humanized IgG1 monoclonal antibody in Phase 1b clinical trials for early Alzheimer's disease that selectively targets toxic amyloid-beta oligomers while avoiding plaque, with the goal of reducing ARIA risk. PMN310 has received FDA Fast Track designation. The company's pipeline also includes PMN267 targeting misfolded TDP-43 for ALS and frontotemporal dementia, and PMN442 targeting pathogenic alpha-synuclein for Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. ProMIS is listed on the Nasdaq exchange and has operations in Cambridge, Massachusetts and Toronto, Ontario. Updated
Insider buying can signal confidence when executives and major shareholders put their own money on the line. While not foolproof, these transactions offer a window into how those closest to a company…
ProMIS Neurosciences is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibodies and vaccines that selectively target toxic oligomers associated with neurodegenerative and other misfolded protein diseases.
The Wall Street consensus 12-month price target for PMN is $42.68.
